Linear Atrophic ScarsNCT07901283
Comparative Analysis of Intralesional Platelet-Rich Plasma, NPH Insulin, and Vitamin C- A New Horizon and Future Hope for Linear Atrophic Scar Management
A study testing Intradermal injection of autologous platelet rich plasma, Intradermal injection of NPH insulin and Intradermal injection of Vitamin C in people with Linear Atrophic Scars, run by Aya Ashraf Fouda at 1 site in Egypt.
Trial summary
The aim of this clinical trial is to evaluate the efficacy and safety of platelet-rich plasma, insulin and vitamin C in the management of linear atrophic scars. The participants were allocated randomly into one of the three groups. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Linear Atrophic Scars
- What is being tested?
- Intradermal injection of autologous platelet rich plasma, Intradermal injection of NPH insulin and Intradermal injection of Vitamin C
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteEgypt
- Study dates
- 10 Mar 2025to 1 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- patients with linear atrophic scars who didn't receive treatments for their scars 6 months before enrollment in the study
Who cannot join
- pregnant and lactating women Patients with history of keloid scars- bleeding and coagulation disorders- autoimmune diseases
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative Study of the Efficacy and Safety of Intralesional Lnjection of Platelet Rich Plasma, Insulin, and Vitamin C for Treatment of Atrophic Scars
The aim of this clinical trial is to evaluate the efficacy and safety of platelet-rich plasma, insulin and vitamin C in the management of linear atrophic scars. The participants were allocated randomly into one of the three groups. The patients will be evaluated at the end of the follow-up period together with assessment of skin thickness using ultrasound before treatment and at the end of follow-up.
Each patient received four treatment sessions at two-week interval
- Conditions
- Linear Atrophic Scars
- Being tested
- Intradermal injection of autologous platelet rich plasma, Intradermal injection of NPH insulin, Intradermal injection of Vitamin C
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intradermal injection of autologous platelet rich plasmaOther
4 sessions at two weeks interval
Intradermal injection of NPH insulinDrug
4 sessions at two weeks interval
Intradermal injection of Vitamin CDrug
Four sessions at two weeks interval
| Study group | Role | What they receive |
|---|---|---|
| Platelet rich plasma injection | Active comparator | Injection of plateler rich plasma Receives: Other: Intradermal injection of autologous platelet rich plasma |
| Injection of NPH insulin | Active comparator | Not described Receives: Drug: Intradermal injection of NPH insulin |
| Injection of Vitamin C | Active comparator | Not described Receives: Drug: Intradermal injection of Vitamin C |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical improvement
Using quartile grading scale
Measured: 2 months after last session
Secondary outcomes (1)
Ultrasound evaluation of skin thickness at the site of scar
Measurement of skin thickness in mm
Measured: Baseline and 2 months after last session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2026
- Study start10 Mar 2025
- Primary completion15 Mar 2026
- Study completion1 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Linear Atrophic ScarsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aya Ashraf Fouda
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Aya Ashraf Fouda, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07901283
- Sponsor's protocol ID
- 36264MS671/8/25
- Status last verified
- Oct 2026
- First submitted
- 22 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study of the Efficacy and Safety of Intralesional Lnjection of Platelet Rich Plasma, Insulin, and Vitamin C for Treatment of Atrophic Scars
- ClinicalTrials.gov ID
- NCT07901283
- Acronym / sponsor ID
- 36264MS671/8/25
- Conditions
- Linear Atrophic Scars
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Aya Ashraf FoudaUniversity, hospital or other
- Study start
- 10 Mar 2025 (actual)
- Primary completion
- 15 Mar 2026 (actual)
- Study completion
- 1 May 2026 (actual)
- First posted
- 28 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this clinical trial is to evaluate the efficacy and safety of platelet-rich plasma, insulin and vitamin C in the management of linear atrophic scars. The participants were allocated randomly into one of the three groups. The patients will be evaluated at the end of the follow-up period together with assessment of skin thickness using ultrasound before treatment and at the end of follow-up.
Each patient received four treatment sessions at two-week interval
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Platelet rich plasma injection | Active comparator | Other: Intradermal injection of autologous platelet rich plasmaInjection of plateler rich plasma |
| Injection of NPH insulin | Active comparator | Drug: Intradermal injection of NPH insulin |
| Injection of Vitamin C | Active comparator | Drug: Intradermal injection of Vitamin C |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- patients with linear atrophic scars who didn't receive treatments for their scars 6 months before enrollment in the study
Key exclusion criteria (1 listed)
- pregnant and lactating women Patients with history of keloid scars- bleeding and coagulation disorders- autoimmune diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intradermal injection of autologous platelet rich plasma4 sessions at two weeks interval | Other | Platelet rich plasma injection |
| Intradermal injection of NPH insulin4 sessions at two weeks interval | Drug | Injection of NPH insulin |
| Intradermal injection of Vitamin CFour sessions at two weeks interval | Drug | Injection of Vitamin C |
Primary outcome
Clinical improvement
Time frame: 2 months after last session
Using quartile grading scale
1 secondary outcome
Ultrasound evaluation of skin thickness at the site of scar
Time frame: Baseline and 2 months after last session
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intradermal injection of autologous platelet rich plasma, Intradermal injection of NPH insulin and Intradermal injection of Vitamin C in people with Linear Atrophic Scars, run by Aya Ashraf Fouda at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical improvement (time frame: 2 months after last session). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.